Spinal Cord Injury Information ::: What You Need To Know
Random video I thought about making for awhile still not sure if I like it but ya xD Information about Spinal Cord Injury and pictures

By: Rachel Griffith

Original post:
Spinal Cord Injury Information ::: What You Need To Know - Video

Recommendation and review posted by sam

2 of 4 Dr. Alexey Aravin at the First Open Institute for Regenerative Medicine for Young Scientists
2 out of 4 Small RNA Pathways in the Germline by Professor Alexey Aravin, California Institute of Technology

By: antiaging

Here is the original post:
2 of 4 Dr. Alexey Aravin at the First Open Institute for Regenerative Medicine for Young Scientists - Video

Recommendation and review posted by sam

4 of 4 Dr. Alexey Aravin at the First Open Institute for Regenerative Medicine for Young Scientists
4 out of 4 Small RNA Pathways in the Germline by Professor Alexey Aravin, California Institute of Technology

By: antiaging

Here is the original post:
4 of 4 Dr. Alexey Aravin at the First Open Institute for Regenerative Medicine for Young Scientists - Video

Recommendation and review posted by sam

3 of 4 Dr. Alexey Aravin at the First Open Institute for Regenerative Medicine for Young Scientists
3 out of 4 Small RNA Pathways in the Germline by Professor Alexey Aravin, California Institute of Technology

By: antiaging

Read more:
3 of 4 Dr. Alexey Aravin at the First Open Institute for Regenerative Medicine for Young Scientists - Video

Recommendation and review posted by sam

Dr. Charles Cantor at the First Open Institute for Regenerative Medicine for Young Scientists
1 out of 5 Regenerative Medicine and Cell Technology: My View on Some Future Trends by Professor Charles Cantor, CSO, Sequenom, Professor Boston University, Professor, University of California Irvine http://www.charlescantor.org http://www.facebook.com

By: antiaging

Here is the original post:
Dr. Charles Cantor at the First Open Institute for Regenerative Medicine for Young Scientists - Video

Recommendation and review posted by sam

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/7pv874/drug_delivery_in) has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering.

Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery for cancer. Cancer drug delivery is no longer simply wrapping up cancer drugs in a new formulations for different routes of delivery. The focus is on targeted cancer therapy. The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent damage to normal tissues and prevent drug resistance.

Innovative cancer therapies are based on current concepts of molecular biology of cancer. These include antiangiogenic agents, immunotherapy, bacterial agents, viral oncolysis, targeting of cyclic-dependent kinases and tyrosine kinase receptors, antisense approaches, gene therapy and combination of various methods. Important methods of immunotherapy in cancer involve use of cytokines, monoclonal antibodies, cancer vaccines and immunogene therapy.

Several innovative methods of drug delivery are used in cancer. These include use of microparticles as carriers of anticancer agents. These may be injected into the arterial circulation and guided to the tumor by magnetic field for targeted drug delivery. Polyethylene glycol (PEG) technology has been used to overcome some of the barriers to anticancer drug delivery. Encapsulating anticancer drugs in liposomes enables targeted drug delivery to tumor tissues and prevents damage to the normal surrounding tissues. Monoclonal antibodies can be used for the delivery of anticancer payloads such as radionucleotides, toxins and chemotherapeutic agents to the tumors.

Antisense oligonucleotides have been in clinical trials for cancer for some time now. RNAi has also been applied in oncology. Small interfering RNAs (siRNAs) can be targeted to tumors and one example is suppression of H-ras gene expression indicating the potential for application in therapy of ovarian cancer. Cancer gene therapy is a sophisticated form of drug delivery for cancer. Various technologies and companies developing them are described. Nucleic acid-based cancer vaccines are also described.

The market value of drug delivery technologies and the anticancer drugs are difficult to separate. Cancer market estimates from 2012-2022 are given according to organs involved and the types of cancer as well as according to technologies. Distribution of the into major regions is also described.

Profiles of 222 companies involved in developing innovative cancer therapies and methods of delivery are presented along with their 249 collaborations. The bibliography contains over 650 publications that are cited in the report.The report is supplemented with 60 tables and 9 figures.

Key Topics Covered:

1. Introduction to cancer therapy

Read this article:
Research and Markets: Drug Delivery in Cancer - Technologies, Markets and Companies - 2013 Report

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/p6tm2n/rnai) has announced the addition of Jain PharmaBiotech's new report "RNAi - Technologies, Markets and Companies" to their offering.

RNA interference (RNAi) or gene silencing involves the use of double stranded RNA (dsRNA). Once inside the cell, this material is processed into short 21-23 nucleotide RNAs termed siRNAs that are used in a sequence-specific manner to recognize and destroy complementary RNA. The report compares RNAi with other antisense approaches using oligonucleotides, aptamers, ribozymes, peptide nucleic acid and locked nucleic acid.

Various RNAi technologies are described, along with design and methods of manufacture of siRNA reagents. These include chemical synthesis by in vitro transcription and use of plasmid or viral vectors. Other approaches to RNAi include DNA-directed RNAi (ddRNAi) that is used to produce dsRNA inside the cell, which is cleaved into siRNA by the action of Dicer, a specific type of RNAse III. MicroRNAs are derived by processing of short hairpins that can inhibit the mRNAs. Expressed interfering RNA (eiRNA) is used to express dsRNA intracellularly from DNA plasmids.

Delivery of therapeutics to the target tissues is an important consideration. siRNAs can be delivered to cells in culture by electroporation or by transfection using plasmid or viral vectors. In vivo delivery of siRNAs can be carried out by injection into tissues or blood vessels or use of synthetic and viral vectors.

Because of its ability to silence any gene once the sequence is known, RNAi has been adopted as the research tool to discriminate gene function. After the genome of an organism is sequenced, RNAi can be designed to target every gene in the genome and target for specific phenotypes. Several methods of gene expression analysis are available and there is still need for sensitive methods of detection of gene expression as a baseline and measurement after gene silencing. RNAi microarray has been devised and can be tailored to meet the needs for high throughput screens for identifying appropriate RNAi probes. RNAi is an important method for analyzing gene function and identifying new drug targets that uses double-stranded RNA to knock down or silence specific genes. With the advent of vector-mediated siRNA delivery methods it is now possible to make transgenic animals that can silence gene expression stably. These technologies point to the usefulness of RNAi for drug discovery.

Regulatory, safety and patent issues are discussed. Side effects can result from unintended interaction between an siRNA compound and an unrelated host gene. If RNAi compounds are designed poorly, there is an increased chance for non-specific interaction with host genes that may cause adverse effects in the host. However, there are no major safety concerns and regulations are in preliminary stages as the clinical trials are still ongoing and there are no marketed products. Many of the patents are still pending.

The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. Various markets relevant to RNAi are analyzed from 2012 to 2022. Markets are also analyzed according to technologies and use of siRNAs, miRNAs, etc.

Profiles of 161 companies involved in developing RNAi technologies are presented along with 229 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Out of these, 33 are developing RNAi-based therapeutics and 34 are involved in microRNAs. The bibliography contains selected 600 publications that are cited in the report. The text is supplemented with 34 tables and 11 figures.

Key Topics Covered:

Read the original:
Research and Markets: RNAi - Technologies, Markets and Companies - 2013 Report

Recommendation and review posted by Bethany Smith

New Delhi, Jan. 18: A promise of anonymity in genomic research may be misleading.

A new study has shown that it is possible to determine the identities of people who have anonymously contributed genetic material for research, exposing gaps in existing security structures for personal genetic information.

A team of US scientists has combined genomic information with Internet search tools and public databases to identify nearly 50 individuals in America who had provided their genetic material as participants in genomic studies.

The researchers used genetic markers found on the Y-chromosome, which moves from father to son to first infer the surnames of the individuals and then used several public databases to determine their identities. The study appears today in the US journal Science.

"Our results show it is possible to identify some individuals who may have wished to remain anonymous," said Yaniv Erlich, principal investigator at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and senior author of the study.

Erlich and his colleagues have not revealed the identities of these individuals but shared their methodology of breaching privacy with senior staff at the US National Institutes of Health before the publication of the research.

The researchers hope the study will stimulate debate and research on policy guidelines and security procedures to protect the privacy of genetic information that can potentially reveal health information about individuals.

"We don't want people to stop donating genetic material and we want the public sharing of data to continue," Erlich told The Telegraph. "This study was intended to help policy makers and individuals appreciate the benefits and the risks of releasing genetic data."

The Whitehead researchers used genetic markers called short-tandem ' repeats on the Y-chromosome or Y-STRs ' that can provide information on paternal lineages when combined with recreational genetic genealogy databases.

The scientists used the two largest public genetic genealogy databases 'www.ysearch.org and http://www.smgf.org ' that are free-of-charge and are equipped with search engines.

Original post:
Study exposes hole in gene security

Recommendation and review posted by Bethany Smith

Gene therapy PowerPoint Template - Gene therapy PowerPoint (PPT) Backgrounds Templates (Download)
Download - beefile.info/apps/download.php?dl=Gene-therapy-PowerPoint-Template---Gene-therapy-PowerPoint-(PPT)-Backgrounds-Templates

By: alan baumen

Read more from the original source:
Gene therapy PowerPoint Template - Gene therapy PowerPoint (PPT) Backgrounds Templates (Download) - Video

Recommendation and review posted by Bethany Smith

Local Non-Profit funds Cancer Research
Watch more and discuss: stamford.itsrelevant.com The Alliance for Cancer Gene Therapy has awarded millions to cancer research. The Stamford-based Alliance was founded by Greenwich residents Edward and Barbara Netter.

By: irstamford

More:
Local Non-Profit funds Cancer Research - Video

Recommendation and review posted by Bethany Smith

Opening of the Penn State Hershey Institute for Personalized Medicine
Opening of the Penn State Hershey Institute for Personalized Medicine View article at lancasteronline.com

By: lancasteronline

Excerpt from:
Opening of the Penn State Hershey Institute for Personalized Medicine - Video

Recommendation and review posted by sam

MANILA, Philippines --- The Department of Health (DOH) is preparing guidelines for the use of stem cell therapy in the treatment of diseases in the Philippines.

This was announced by DOH Secretary Enrique T. Ona yesterday in a convention on stem cell therapy at the Manila Hotel.

Ona said a bio-ethics advisory board will develop the guidelines which will include ethical standards in the application of stem cell therapy to treat diseases such as malignancies, blood disorders and metabolic disorders, among others.

"The institutional board will review and approve Stem Cell therapies based on guidelines by the advisory board," Ona said.

He added that the board will also include ethical and legal issues surrounding stem cell therapy.

Last week, the Philippine Medical Association (PMA) and the Philippine Society for Stem Cell Medicine (PSSCM) issued a joint statement that warned against the dangers of receiving stem cell transplants that came from another source other than the patient's body.

"If the stem cell that you received is not from your own body, it could lead to fatal complications," Philippine Society for Stem Cell Medicine (PSSCM) and the PMA said.

The doctors warned that complications arising from stem cell transplants include graft-versus-host disease, stem cell (graft) failure, organ injury, infections, cataracts, infertility, new cancers, and even death.

Ona said a public hearing will be held on January 18 regarding the preliminary draft of the guidelines.

He said the guidelines will ensure the minimum quality of service and application in the use of stem cells in health settings.

See the article here:
Stem Cell Therapy Guidelines Readied

Recommendation and review posted by Bethany Smith

SILVER SPRING, Md., Jan. 17, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), an international biotechnology company providing natural products and cell and gene therapy solutions for the treatment of human diseases, announced today that its technologies, Cell-in-a-Box(R) and Bac-in-a-Box(R), developed by its subsidiary Austrianova Singapore (ASPL), have been recognized and profiled by the non-profit company, Intellectual Property Intermediary Singapore (IPI Singapore).

The Cell-in-a-Box(R) and Bac-in-a-Box(R) products are proprietary living eukaryotic and bacterial cell encapsulation technological platforms developed by ASPL that can be used for a variety of living cell types. Both of them are unique platform technologies with the potential for such diverse uses as antibody production, treatment of diabetes, part of pancreatic cancer treatment regimen, treatments that employ stem cells, and for the improved use of probiotics, to name a few.

The technologies have been shown to be robust for manipulations and injections and are non-immunogenic. They can be frozen with cells inside that can be recovered years later, and they allow cells to be expanded inside the capsules as mini bioreactors. Moreover, the technology has been shown to be safe and effective for multiple diseases in animal models as well as in human clinical trials for pancreatic cancer.

IPI Singapore was launched in April 2011 as part of the Singapore Research, Innovation, and Enterprise 2015 Plan to contribute to the innovation and enterprise ecosystem in Singapore. IPI's overall aims include helping companies "identify, source, scan and assess technologies" as well as "facilitate technology transfer."

The President and CEO of Nuvilex, Dr. Robert Ryan, stated, "We are pleased IPI Singapore has recognized our technology and will provide access to information about the technologies developed by our ASPL subsidiary. We believe our Company will receive increased exposure to the business and scientific communities due to the recognition by IPI Singapore. Through this recognition and our ongoing efforts, we hope to develop multiple unique products for commercialization from the Cell-in-a-Box(R) and Bac-in-a-Box(R) technology platforms."

About Nuvilex

Nuvilex, Inc. (OTCQB:NVLX) has been a provider of all-natural products for many years and has expanded its company to become an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine. In the biotechnology area of Nuvilex, enhanced antibody production capabilities through encapsulation, our company's offerings will include cancer, diabetes, and other clinical treatments using the company's cell and gene therapy expertise and live-cell encapsulation technology.

The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494

Safe Harbor Statement

This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

View post:
Nuvilex Technologies Recognized by the Singaporean Intellectual Property Intermediary, IPI Singapore

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/8xfhl4/antiviral) has announced the addition of Jain PharmaBiotech's new report "Antiviral Therapeutics - Technologies, Markets and Companies" to their offering.

This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics. The introduction starts with a practical classification of viral diseases according to their commercial importance. Various antiviral approaches are described including pharmaceuticals and molecular biological therapies such as gene therapy and RNA interference (RNAi) as well as vaccines for virus infections. Expert opinion is given about the current problems and needs in antiviral therapy. SWOT (strengths, weaknesses, opportunities and threats) analysis of antiviral approaches is presented against the background of concept of an ideal antiviral agent.

A novel feature of this report is the use of nanotechnology in virology and its potential for antiviral therapeutics. Interaction of nanoparticles with viruses are described. NanoViricides are polymeric micelles, which act as nanomedicines to destroy viruses. Various methods for local as well as systemic delivery of antiviral agents and vaccines are described. Nanobiotechnology plays an important role in improving delivery of antivirals. Advantages and limitations of delivery of gene-based, antisense and RNAi antiviral therapeutics are discussed.

Markets for antivirals are considered according to viruses and diseases caused by them and also according to management approaches: antiviral drugs, vaccines, MAbs and innovative approaches that include immunological and use of other technologies such as gene therapy, antisense, RNAi and nanobiotechnology. Antiviral markets are estimated starting with 2012 with projections up to the year 2022.

Profiles of 178 companies that are involved in developing various technologies and products are profiled and with 167 collaborations. These include major pharmaceutical companies (13), Biopharmaceutical companies with antiviral products (80), Antiviral drug companies (25) as well as viral vaccine companies (60). The report is supplemented with 50 tables, 11 figures and 470 references from the literature.

Key Topics Covered:

Executive Summary

1. Introduction to Virology

2. Antiviral Approaches

Read the original here:
Research and Markets: Antiviral Therapeutics - Technologies, Markets and Companies - 2013

Recommendation and review posted by Bethany Smith

Jews of European origin are a mix of ancestries, with many hailing from tribes in the Caucasus who converted to Judaism and created an empire that lasted half a millennium, according to a gene study.

The investigation, its author says, should settle a debate that has been roiling for more than two centuries.

Jews of European descent, often called Ashkenazis, account for some 90 percent of the more than 13 million Jews in the world today.

According to the so-called Rhineland Hypothesis, Ashkenazis descended from Jews who progressively fled Palestine after the Moslem conquest of 638 AD.

They settled in southern Europe and then, in the late Middle Ages, about 50,000 of them moved from the Rhineland in Germany into eastern Europe, according to the hypothesis.

But detractors say this idea is implausible.

Barring a miracle --which some supporters of the Rhineland Hypothesis have in fact suggested -- the scenario would have been demographically impossible.

It would mean that the population of Eastern European Jews leapt from 50,000 in the 15th century to around eight million at the start of the 20th century.

That birth rate would have been 10 times greater than that of the local non-Jewish population. And it would have occurred despite economic hardship, disease, wars and pogroms that ravaged Jewish communities.

Seeking new light in the argument, a study published in the British journal Genome Biology and Evolution, compares the genomes of 1,287 unrelated individuals who hail from eight Jewish and 74 non-Jewish populations.

Continue reading here:
Gene study settles debate over origin of European Jews

Recommendation and review posted by Bethany Smith

People who have a certain variant of the ABCC11 gene don't produce under arm odor, though many of them still wear deodorant, Bristol University researchers report in the Journal of Investigative Dermatology. (The variant is also linked to dry earwax.)

Drawing on about 17,000 people from the Avon Longitudinal Study of Parents and Children study, the researchers investigate how having the ABCC11 rs17822931 variant affects people's hygiene behavior. People who are homozygotes for the rs17822931 A allele are five times less likely to use deodorant than GG homozygotes and heterozygotes are, they find.

However, the researchers note that nearly 80 percent of white European mothers in the study who, based on their genotype, should not produce under arm odor still wear deodorant and that that behavior is likely socially and culturally driven.

"This effect has a biological basis that can result in a change in the family's environment if an aerosol deodorant is used. It also indicates potential cost saving to the nonodorous and scope for personalized genetics usage in personal hygiene choices, with consequent reduction of inappropriate chemical exposures for some," the researchers add.

Read the original here:
The Deodorant Gene …

Recommendation and review posted by Bethany Smith

PARK CITY, Utah--(BUSINESS WIRE)--

Rejuvenation Labs today announced the launch of Resvology, the only topical anti-aging skin care line containing the multi-patented, gene-activating 4-AR Molecule, a uniquely stabilized ester form of the widely recognized youth molecule resveratrol.

Resvologys anti-aging effectiveness is based upon a proprietary molecule discovered by a team of cancer researchers at Brigham Young University working under a grant by the National Institutes of Health. Through in-vitro studies, the 4-AR Molecule (or resveratryl acetate) has been observed to activate 85 key skinrelated genes to fuel gene activity, including:

Unveiled at the Sundance Film Festival, the Resvology Age Corrective collection consists of three core products designed for all skin types: the Age Corrective Wrinkle Treatment, Age Corrective Eye Cream and the Gentle Cleansing Gel. These products work together to hydrate and smooth skin texture and reduce signs of aging, helping keep skin looking firm, lifted and youthful.

Researchers also observed a significant correlation between the 4-AR Molecule in higher production of several proteins and enzymes important to cell regeneration. In clinical trials, consumers have reported that Resvology hydrated skin, removed fine lines and wrinkles, and minimized puffiness and dark circles around the eyes.

The discovery of the 4-AR Molecule has improved our understanding of the skins aging process, and how it can look and feel more youthful, said Kevin Passey, CEO of Rejuvenation Labs. Resvology sets a new standard for anti-aging effectiveness in the skin care industry by creating the most stable and accessible use of resveratrol. Resvology will make a genuine difference in how women look and feel.

The science behind the 4-AR Molecule captured the early attention of entrepreneurs Gary Crocker and Dinesh Patel, two leading life science experts who have each founded numerous successful biotechnology companies. Crocker and Patel are members of the board of directors of Rejuvenation Labs, and together they are providing substantial financial backing for the launch of Resvology.

Crocker has founded multiple successful medical device companies, including Research Medical, which became the worlds largest supplier of cardiac bypass catheters before it was acquired by Baxter International for $250 million. Crocker is currently chairman of Merrimack Pharmaceuticals, a leader in oncology research and treatment, and CEO of Crocker Ventures. Patel, one of the leading fathers of biotechnology in the Mountain West region, has led or helped launch many companies. Holder of numerous patents, Patel was also CEO of Theratech, a leader in drug delivery technology that he co-founded with Crocker. Theratech was purchased by Watson Pharmaceuticals.

It is exciting to be part of a team of scientists and business leaders that are creating an innovative skin care line with observable results, said Crocker. The discovery of the 4-AR Molecule and the quality of the scientific and business teams made it clear that this is more than just another skin care line. Rejuvenation Labs will make a major impact in the beauty care market.

Resvology will roll out in the first quarter of 2013 and be sold at specialty retailers. For more information, visit http://www.resvology.com.

Originally posted here:
Resvology Launches Anti-Aging Skin Care Line with Patented Gene-Activating Molecule

Recommendation and review posted by Bethany Smith

Editor's Choice Academic Journal Main Category: Autism Also Included In: Genetics Article Date: 16 Jan 2013 - 12:00 PST

Current ratings for: New Gene Variants Linked To Autism Discovered

2 (1 votes)

The research team, led by Hakon Hakonarson, MD, PhD, explained in the journal PLOS ONE that they identified 25 additional copy number variants (CNVs) that occur in some people with autism. CNVs are duplicate or missing stretches of DNA.

They describe these copy number variants as individually rare, but of "high impact", meaning that each one has a strong effect in increasing a person's risk for autism.

Dr. Hakonarson said:

Scientists from the Seaver Autism Center at Icahn School of Medicine at Mount Sinai said that there are hundreds of mutated genes linked to ASDs.

In this study, the team initially analyzed the DNA of 55 people from families in Utah with multiple members who had been diagnosed with ASDs. The data from high-risk families had been collected by Mark Leppert, PhD. They identified 153 CNVs as potentially linked to autism.

The team wanted to look at these CNVs in a broader ASD population. They custom-designed a DNA array with probes for all 153 CNVs, as well as an additional 185 CNVs which had been linked to autism in previous studies. They gathered and examined all the data to determine how common all the CNVs were in 3,000 people with an ASD and 6,000 control subjects previously gathered in studies carried out at The Children's Hospital of Philadelphia.

The researchers found that:

Read the original:
New Gene Variants Linked To Autism Discovered

Recommendation and review posted by Bethany Smith

Newswise Melanomas that develop in the eye often are fatal. Now, scientists at Washington University School of Medicine in St. Louis report they have identified a mutated gene in melanoma tumors of the eye that appears to predict a good outcome.

The research is published in the advance online edition of Nature Genetics.

We found mutations in a gene called SF3B1, says senior author Anne Bowcock, PhD, professor of genetics. The good news is that these mutations develop in a distinct subtype of melanomas in the eye that are unlikely to spread and become deadly.

Eye tumors called uveal melanomas occur in about 2,000 patients a year, making up about 5 percent of all melanomas. In many patients, there are no symptoms, and the tumors become fatal when they spread to the liver.

Several years ago, Bowcock and the studys lead author, J. William Harbour, MD, a former Washington University eye surgeon who is now at the University of Miami, identified a commonly mutated gene, BAP1, in patients with uveal melanomas.

They found BAP1 alterations in about 80 percent of uveal melanomas with a poor prognosis, called class II tumors. About 75 percent of patients with these tumors die within five years, a sharp contrast to the generally favorable outcomes of patients whose tumors dont have BAP1 mutations, called class I.

For the new study, Bowcock and her colleagues initially sequenced the DNA of uveal melanomas from 18 patients whose BAP1 status was already known. Seven had no BAP1 mutations (class I tumors), and 11 had BAP1 mutations (class II tumors).

The researchers analysis uncovered alterations in the SF3B1 gene in three of the patients.

This is the first time mutations in this gene have been found in uveal melanoma, says Bowcock, who also is a professor of pediatrics and of medicine.

As part of the current study, the researchers also looked for SF3B1 mutations in uveal melanoma tumors from 102 patients, finding it in nearly 20 percent of them. Mutations in the gene were linked to favorable features, including a younger age at diagnosis and a far lower metastasis rate.

Continued here:
Gene in Eye Melanomas Linked to Good Prognosis

Recommendation and review posted by Bethany Smith

Public release date: 17-Jan-2013 [ | E-mail | Share ]

Contact: Matt Fearer fearer@wi.mit.edu 617-452-4630 Whitehead Institute for Biomedical Research

CAMBRIDGE, Mass. (January 17, 2013) Using only a computer, an Internet connection, and publicly accessible online resources, a team of Whitehead Institute researchers has been able to identify nearly 50 individuals who had submitted personal genetic material as participants in genomic studies.

Intent on conducting an exercise in vulnerability researcha common practice in the field of information securitythe team took a multi-step approach to prove that under certain circumstances, the full names and identities of genomic research participants can be determined, even when their genetic information is held in databases in de-identified form.

This is an important result that points out the potential for breaches of privacy in genomics studies, says Whitehead Fellow Yaniv Erlich, who led the research team. A description of the groups work is published in this weeks Science magazine.

Erlich and colleagues began by analyzing unique genetic markers known as short tandem repeats on the Y chromosomes (Y-STRs) of men whose genetic material was collected by the Center for the Study of Human Polymorphisms (CEPH) and whose genomes were sequenced and made publicly available as part of the 1000 Genomes Project. Because the Y chromosome is transmitted from father to son, as are family surnames, there is a strong correlation between surnames and the DNA on the Y chromosome.

Recognizing this correlation, genealogists and genetic genealogy companies have established publicly accessible databases that house Y-STR data by surname. In a process known as surname inference, the Erlich team was able to discover the family names of the men by submitting their Y-STRs to these databases. With surnames in hand, the team queried other information sources, including Internet record search engines, obituaries, genealogical websites, and public demographic data from the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository at New Jerseys Coriell Institute, to identify nearly 50 men and women in the United States who were CEPH participants.

Previous studies have contemplated the possibility of genetic identification by matching the DNA of a single person, assuming the persons DNA were cataloged in two separate databases. This work, however, exploits data between distant paternally-related individuals. As a result, the team notes that the posting of genetic data from a single individual can reveal deep genealogical ties and lead to the identification of a distantly-related person who may have no acquaintance with the person who released that genetic data.

We show that if, for example, your Uncle Dave submitted his DNA to a genetic genealogy database, you could be identified, says Melissa Gymrek, a member of the Erlich lab and first author of the Science paper. In fact, even your fourth cousin Patrick, whom youve never met, could identify you if his DNA is in the database, as long as he is paternally related to you.

Aware of the sensitivity of his work, Erlich emphasizes that he has no intention of revealing the names of those identified, nor does he wish to see public sharing of genetic information curtailed.

More here:
Scientists expose new vulnerabilities in the security of personal genetic information

Recommendation and review posted by Bethany Smith

CHICAGO, Jan. 17, 2013 (GLOBE NEWSWIRE) -- The American Medical Association (AMA) announced an agreement with the National Library of Medicine that will enhance the National Institutes of Health's Genetic Testing Registry, a centralized public source for information on genetic tests.

Under the agreement, Current Procedural Terminology (CPT(R)) codes for molecular pathology tests will be integrated into the publicly available Genetic Testing Registry (GTR), which is managed by the National Center for Biotechnology Information, a division of the National Library of Medicine at NIH. The AMA-created CPT codes describe the latest advances in genetic testing and molecular diagnostic services for reporting and tracking purposes.

"Incorporating these CPT codes into GTR will help clinicians pinpoint practical information about genetics in a centralized resource," said GTR Director Wendy Rubinstein, M.D., Ph.D.

"CPT codes are a critical element to building an infrastructure that supports moving new genetic discoveries to the front lines of clinical care as we move into an era of personalized medicine," said AMA President Jeremy A. Lazarus, M.D. "Adding a CPT coding reference to the Genetic Testing Registry gives physicians an invaluable information source that will enhance the reporting of genetic tests and services."

The AMA has been involved with coding solutions for molecular pathology services since 1998. New, more detailed CPT codes for molecular pathology became effective in 2012 to capture and describe the latest scientific advances in this rapidly expanding field of medicine. The ongoing process has so far created more than 100 codes for reporting innovative diagnostic services, and advances the AMA's overarching goal of reducing disease burdens, improving health outcomes and reducing long-term care costs.

Media Contact: Robert J. Mills AMA Media Relations (312) 464-5970 robert.mills@ama-assn.org

About the American Medical Association (AMA)

The American Medical Association helps doctors help patients by uniting physicians nationwide to work on the most important professional, public health and health policy issues. The nation's largest physician organization plays a leading role in shaping the future of medicine. For more information on the AMA, please visit http://www.ama-assn.org.

This information was brought to you by Cision http://www.cisionwire.com http://www.cisionwire.com/american-medical-association/r/ama-enhances-genetic-testing-registry,c9358492

Continued here:
AMA Enhances Genetic Testing Registry

Recommendation and review posted by Bethany Smith

The Week at Duke {in 60 Seconds}: Gun Debate; MLK Address; Bryan Center
Duke University juniors Danny Nolan and Emily Sobel deliver a week #39;s worth of campus news in a minute. Duke faculty and students have been weighing in on the national debate about gun policy. One prominent voice in the debate is public policy professor Phil Cook. "I think we are at a point now that is much like we were in the 1980s with drunk driving," Cook said. "MADD and other organizations worked hard to get judges to treat that as a serious crime and I think now we have to make sure that the judges take illegal carrying of guns as a serious crime." A new study led by Duke doctor Barton Haynes helps scientists better understand how an experimental HIV vaccine works -- and where it fails. The keynote address at Duke #39;s Martin Luther King Junior celebration January 20 will be given by Duke Divinity School professor, the reverend William Turner. Biology professor Mohamed Noor is teaching a free online course on evolution and genetics on the Coursera platform. The Bryan Center is getting a makeover. It will eventually look like this. For more Duke news everyday, visit Duke Today at today.duke.edu.

By: Duke

More:
The Week at Duke {in 60 Seconds}: Gun Debate; MLK Address; Bryan Center - Video

Recommendation and review posted by Bethany Smith

I feel for u
Just hear her out an think on your time to know an see what your brain DNA genetics produce? Brain gene activity changes through life Body Brain.

By: Woweetime Morecolor

Read the rest here:
I feel for u - Video

Recommendation and review posted by Bethany Smith

J Love Natural Hair Care
J Love maker of Genetics, Progenics, Variations, professional hair care systems I created this video with the YouTube Video Editor (www.youtube.com

By: Joseph Love

See the article here:
J Love Natural Hair Care - Video

Recommendation and review posted by Bethany Smith

The Hidden Source Episode 36 -RQ RQ RQ THEY ALL SUCK-
Myself ThatOneRebel playing some The Hidden Source! Nobody can see The Hidden only trained eyes can see him well! WATCH AS I MURDER EVERYONE AS THE HIDDEN MAHAAAHAHAHA The objective of The Hidden Source is that the humans aka IRIS must eliminate The Hidden to win vice versa for the Hidden but as the title says he is invisible and only is equipped with a knife capable of a one hit kill depending on server and only three grenades. The hidden has many abilities like taunting, super strength to ram objects into IRIS soldiers or be able to leap super high and hang on buildings. Lastly The Hidden can heal himself by eating bodies but only if they are stabbed to death not PIGSTICKED! (which is the one hit kill move) The IRIS are equipped with four weapons ranging from shotgun to rifle to SMG and a few options of equipment like senors to laser optics on your gun. Game is The Hidden Source which requires Half life 2 engine meaning you have to have Half Life 2 purchased already or another source game to run with STORYLINE In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid ...

By: ThatOneRebel55

Read more:
The Hidden Source Episode 36 -RQ RQ RQ THEY ALL SUCK- - Video

Recommendation and review posted by Bethany Smith